A conferência “Framework, science and technology for pre-clinical studies with radiopharmaceuticals: the state of the art” será apresentada no dia 30 de agosto pelo Prof. David Stout, PhD.
Prof. David Stout, PhD, é diretor do Crump Institute for Molecular Imaging, Univerisdade de Los Angeles California (UCLA). Trabalha com microPET, microCT e equipamentos para autoradiografia e fluorescência em pesquisas com imagem molecular. Desenvolve experimentos toxicológicos e de dosimetria para novos compostos PET desde a pesquisa em laboratório com animais até o uso clínico em seres humanos.
Publicou 70 artigos em periódicos indexados e 86 trabalhos completos em congressos e eventos científicos.
Prof. Stout é revisor das seguintes revistas científicas:
– Journal of Nuclear Medicine
– Molecular Imaging and Biology
– American Association of Physicists in Medicine, Medical Physics
– IEEE Transactions on Nuclear Science
– Physics in Medicine and Biology
Também publicou capítulos nos seguintes livros:
– Animal Handling and Preparation For Imaging. Editor Habib Zaidi, Elsevier Press, 2009
– How to set up a small animal imaging unit. Editor Bernd Pichler, Springer, 2009
– Education of staff and personnel for imaging centers. Editor Bernd Pichler, Springer, 2009
– Imaging Sciences in Advanced Drug Development; Animal Models, Handling & Physiologic Constraints. Springer, 2012
Prof. Stout desenvolveu as seguintes patentes nos EUA:
– Method and apparatus for animal positioning in imaging systems 2005 PCT/US05/28792
– PETbox: A desktop mouse PET scanner: 2009
– Mouse Cage redesign, provisional patent filed Oct. 2013
– Mouse Imaging chamber, invention report filed Oct. 2013
RESUMO DA CONFERêNCIA DO DIA 30 DE AGOSTO:
From four decades ago the scientific and technological growth in radiochemistry and nuclear instrumentation allowed radiopharmaceutical become an important tool for diagnostic medicine, as nuclear medicine, for detection of organ dysfunction mainly based in blood perfusion studies or other “nonspecific” changes as osteoclastic/osteoblastic activities in the tumor bone. However, the continuous improvement in this area, during last two decades, associated with development in cell biology, took us to a high level, allowing detect, by imaging, activity of enzymes, expression of specific receptor in cells, and other molecular process. To imaging those events is necessary specific radioactive probes and it has been done with relative facility but, the problem is how prove the efficiency and non risk for human use. Pre-clinical studies start during in vitro procedures, necessary to check specificity of a probe to bind specific target, next step the same probe is evaluated in an animal models, where physiological aspect could change in vitro results. Furthermore, moving to animal models, we could need specific animal models, as knockout for expressing proteins or other receptors, and add difficulties regards to sensitivity of scanners to detect the probes, given quantitative and qualitative values. In nuclear imaging instrumentation, focused in pre-clinical devices, the advances were strong, including hybrid systems with PET or SPECT conjugated with CT, NMR or fluorescence. In this conference I plan to demonstrated the state of art of radioactive probes, animal handling and equipments and their role for pre-clinical and molecular imaging future.